Hey readers! Here's something that might surprise you: the first approved immunotherapy for newly diagnosed kids with Type 1 doesn't lower blood sugar at all. It goes after the immune process itself. This week we've got a fresh clinical roadmap for using it, a first NHS patient, two new pumps, and the WHO's first-ever T1D guidelines. Let's dig in.
🧭 A roadmap for teplizumab in newly diagnosed kids

CU Anschutz–Led Team Publishes National Roadmap for First Approved Immunotherapy for Newly Diagnosed Type 1 Diabetes in Children lays out, in Diabetes Care, how pediatric teams can actually fold teplizumab into real-world care for children ages 8 to 17 newly diagnosed with stage 3 T1D.
– Breakthrough T1D, Nov 11, 2026
This matters because the FDA expanded teplizumab's approval in June 2026 specifically to delay further loss of insulin production in recently diagnosed kids and teens. Until now, the standard answer at diagnosis was insulin and insulin alone. The guidance is endorsed by Breakthrough T1D and the Pediatric Endocrine Society, and it tackles the practical stuff: who's a good candidate, how to run shared decision-making with families, and how to start treatment within eight weeks of diagnosis.
"Insulin is essential in stage 3 type 1 diabetes, but it doesn't address the immune process that is destroying the cells that make insulin," said Simmons. "Teplizumab gives us an opportunity to preserve some of the beta cells and insulin-producing capacity that a person still has. The goal is to intervene early enough to make a meaningful difference."
The logistics are not trivial. Treatment runs as two 12-day courses of daily IV infusions, usually about six months apart, with monitoring for risks like cytokine release syndrome, infections, and viral reactivation. One line from the guidance stood out as a quietly important design principle:
"We don't want to create a separate pathway that fragments care," said Simmons. "This is an opportunity to be thoughtful about how we use a new therapy while keeping the whole patient in view."
That's the right instinct. A disease-modifying drug only helps if it fits into the coordinated care a child already needs.
Teplizumab hits the clinic in two places

The roadmap isn't theoretical. Two real-world moves landed the same week:
Lurie Children's Offers New Type 1 Diabetes Drug Tzield says the Chicago hospital has started treating its first pediatric patient in the newly eligible group. Consistent with the roadmap, eligibility is ages 8 to 17, diagnosed with stage 3 T1D within the previous eight weeks, and still showing evidence of remaining insulin production. – Hoodline, Nov 14, 2026
First NHS patient in UK receives teplizumab to delay symptomatic type 1 diabetes covers Annette Quilter, a 42-year-old GP in Shropshire, who became the first UK patient to get teplizumab in routine NHS use. Worth noting: her approval is for confirmed stage 2 disease, a different (earlier) use than the US pediatric stage 3 roadmap. – Diabetes.co.uk, Nov 16, 2026
Those two stages are easy to conflate, so it's worth being precise. The US expansion is about delaying further insulin-production decline after a stage 3 diagnosis. The UK stage 2 use is about delaying progression to symptomatic disease, by an average of roughly 32 months per the Diabetes.co.uk piece. Neither is a cure, and neither regenerates beta cells already lost. The common thread is that both ask families to show up for daily hospital infusions over about two weeks, which is a genuine burden to plan around.
🧪 A simpler immunotherapy in the pipeline
Teplizumab isn't the only immune-targeting antibody in play, and a potential competitor is positioning itself squarely on convenience.

UF $5.5M Trial Tests Drug to Slow Type 1 Diabetes describes PRISE-hATG, a randomized, double-blind, placebo-controlled trial of the experimental IV drug SAB-142, led by UF's Michael Haller and enrolling people with stage 3 T1D diagnosed between 100 days and two years earlier.
– Hoodline, Nov 13, 2026
Like teplizumab, SAB-142 targets the T cells driving the autoimmune attack, with the goal of slowing beta-cell loss. UF Health is careful to note it is not a cure. The study notably widens the treatment window well past the eight-week deadline that teplizumab requires, which could matter for the many people who don't catch their diagnosis right away. UF Health also discloses that Haller has equity and a role with SAB Biotherapeutics, worth keeping in mind.
SAB BIO at Jefferies Global Healthcare Conference: type 1 diabetes push adds the company's pitch: SAB-142 as a 2-day regimen versus teplizumab's 12-day continuous dosing, with top-line data from the pivotal Phase IIb SAFEGUARD study expected in 2027.
– Investing.com, Nov 16, 2026
The honest read: a shorter course would be a meaningful quality-of-life improvement for families, but SAFEGUARD data is still a year out, and PRISE-hATG is only beginning to enroll. For now, teplizumab is the approved option, and these are promising reasons to watch the space.
🔧 Two new pumps and a CGM integration
Device news came in a cluster this week, and all three items are about reducing daily friction.

MiniMed Launches MiniMed Flex, its Smallest and Most Discrete Insulin Pump, in Europe started commercial shipments across Europe on Nov 17. It's MiniMed's first app-controlled pump, with a screenless design, the SmartGuard algorithm, up to 300 units of insulin, and CE marking for ages two and up.
– MiniMed, Nov 16, 2026
One clinician's observation captured why discretion is its own feature:
"In my early experience with MiniMed Flex, what stands out is how adults who have been living with type 1 diabetes for years respond to a pump that stays out of sight and is controlled from their phone," said Dr. Sharona Azriel.
Meanwhile in the US:
MiniMed gets FDA nod for tubeless insulin pump covers the MiniMed Fit, the company's first tubeless patch pump, cleared for ages seven and up with up to seven-day wear and a 300-unit reservoir. A spring 2027 phased US launch is planned, with Simplera Sync and Abbott's Instinct sensor compatibility. – MedTech Dive, Nov 16, 2026
Senseonics and Beta Bionics Launch Eversense 365 and iLet Bionic Pancreas Integration pairs iLet's fully adaptive automated insulin delivery with Eversense 365's one-year implantable sensor, fulfilling a Q4 2026 launch commitment. – GlobeNewswire, Nov 16, 2026
The through-line here: longer wear, smaller footprint, and algorithms that catch missed or underestimated boluses. None of these replaces attention, but each shaves off a bit of the mental load.
🌍 WHO's first T1D guidelines

WHO issues first guidelines on type 1 diabetes for adults marked World Diabetes Day 2026 with recommendations built for all settings, including low-resource and humanitarian contexts.
– WHO, Nov 13, 2026
WHO reports that in 2025 around 9.5 million people lived with T1D globally, with an additional 500,000 diagnosed that year. There's a companion WHO guideline for children and adolescents up to age 19, covering everything from urine dipstick testing when blood glucose measurement isn't available, to DKA and hypoglycemia management.
"Insulin is a lifesaving treatment, discovered more than 100 years ago. Yet many people with type 1 diabetes do not have access to affordable and high-quality insulin."
That quote is a useful counterweight to all the pump and immunotherapy excitement above. For a large share of the world, the gap isn't the newest algorithm, it's reliable insulin and a glucose meter. WHO is tying this to its 2030 access targets.
🔬 Quick hits from the lab
A few earlier-stage findings worth a bookmark, with the usual caveat that preclinical work takes years to translate:
Exocrine pancreas biomarkers predict T1D risk: ENDIA study found that in a cohort of 216 high-risk children, faecal elastase-1 was lower in the first six months of life among those who later developed persistent islet autoantibodies and T1D, while immunoreactive trypsin differences emerged 12 to 18 months before diagnosis. These could help stratify risk for future prevention trials. – The Limbic, Nov 11, 2026
IIT Kanpur researchers find immune cell 'off switch' for insulin reports that pancreatic macrophages can rapidly suppress insulin release from otherwise healthy beta cells via the receptor GPR18, a potential future drug target. Still preclinical. – News18, Nov 14, 2026
Study distinguishes three forms of adult-onset Type 1 diabetes from German researchers identified three subgroups in adults with recently diagnosed T1D, including a "mixed" type that blends T1D and T2D features but appears to share the same autoimmune process. A reminder that adult-onset T1D is real and often misclassified. – idw / DDZ, Nov 16, 2026
🤝 Community corner
Breakthrough T1D and Walgreens Foundation Join Forces announced a national partnership with a $1 million direct cash commitment over three years and a goal to raise $15 million through checkout campaigns starting May 2027. – PR Newswire, Nov 12, 2026
The Savvy Diabetic's 11/16 update flags a Tandem Mobi pump recall over false occlusion alarms that can suspend delivery, so have a backup insulin plan, plus a free T1Dto100 webinar on mealtime support for Wednesday, Nov 18. – The Savvy Diabetic, Nov 16, 2026
That's the issue. The headline takeaway: teplizumab now has a practical playbook for newly diagnosed kids, and the field around it is getting more crowded in a good way. See you next week.
